Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
Formoterol fumarate inhalation powder for asthma and COPD approved in Germany
July 24th, 2005
SkyePharma PLC (SKP) announced that the German pharmaceutical regulatory authority has approved Foradil Certihaler (formoterol fumarate inhalation powder) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Foradil Certihaler was co-developed by SkyePharma PLC and Novartis Pharma AG and is a trademark of Novartis. Foradil Certihaler was submitted for regulatory review in Europe on a country-by-country basis beginning in December 2002 and has now been approved in Switzerland, Austria, Finland, Portugal and the Netherlands as well as in Germany. It has also been approved in 5 countries in Latin America. It was also submitted for regulatory review...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
